Patent ID: 11932702
Assignee: ABLYNX N.V.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 17:
18. A polypeptide that comprises at least two immunoglobulin single variable domains (ISVDs), wherein each of said ISVDs comprises three complementarity determining regions (CDRs), CDR1 to CDR3, respectively, and wherein:
a) each of a first and a second ISVD specifically binds to Glypican-3 (GPC3) and comprises:
i. a CDR1 consisting of the amino acid sequence of SEQ ID NO: 7;
ii. a CDR2 consisting of the amino acid sequence of SEQ ID NO: 11; and
iii. a CDR3 consisting of the amino acid sequence of SEQ ID NO: 15;

b) each of a first and a second ISVD specifically binds to GPC3 and comprises:
i. a CDR1 consisting of the amino acid sequence of SEQ ID NO: 8;
ii. a CDR2 consisting of the amino acid sequence of SEQ ID NO: 12; and
iii. a CDR3 consisting of the amino acid sequence of SEQ ID NO: 16;

c) a first ISVD specifically binds to GPC3 and comprises:
i. a CDR1 consisting of the amino acid sequence of SEQ ID NO: 7;
ii. a CDR2 consisting of the amino acid sequence of SEQ ID NO: 11; and
iii. a CDR3 consisting of the amino acid sequence of SEQ ID NO: 15; and

 a second ISVD specifically binds to GPC3 and comprises:
iv. a CDR1 consisting of the amino acid sequence of SEQ ID NO: 8;
v. a CDR2 consisting of the amino acid sequence of SEQ ID NO: 12; and
vi. a CDR3 consisting of the amino acid sequence of SEQ ID NO: 16;

d) a first ISVD specifically binds to GPC3 and comprises:
i. a CDR1 consisting of the amino acid sequence of SEQ ID NO: 8;
ii. a CDR2 consisting of the amino acid sequence of SEQ ID NO: 12; and
iii. a CDR3 consisting of the amino acid sequence of SEQ ID NO: 16; and

 a second ISVD specifically binds to GPC3 and comprises:
iv. a CDR1 consisting of the amino acid sequence of SEQ ID NO: 7;
v. a CDR2 consisting of the amino acid sequence of SEQ ID NO: 11; and
vi. a CDR3 consisting of the amino acid sequence of SEQ ID NO: 15;

e) a first ISVD specifically binds to the constant domain of a T cell receptor (TCR) on a T cell and comprises:
i. a CDR1 consisting of the amino acid sequence of SEQ ID NO: 6;
ii. a CDR2 consisting of the amino acid sequence of SEQ ID NO: 10; and
iii. a CDR3 consisting of the amino acid sequence of SEQ ID NO: 14; and

 a second ISVD specifically binds to GPC3 and comprises:
iv. a CDR1 consisting of the amino acid sequence of SEQ ID NO: 7;
v. a CDR2 consisting of the amino acid sequence of SEQ ID NO: 11; and
vi. a CDR3 consisting of the amino acid sequence of SEQ ID NO: 15;

f) a first ISVD specifically binds to GPC3 and comprises:
i. a CDR1 consisting of the amino acid sequence of SEQ ID NO: 7;
ii. a CDR2 consisting of the amino acid sequence of SEQ ID NO: 11; and
iii. a CDR3 consisting of the amino acid sequence of SEQ ID NO: 15; and

 a second ISVD specifically binds to the constant domain of a TCR on a T cell and comprises:
iv. a CDR1 consisting of the amino acid sequence of SEQ ID NO: 6;
v. a CDR2 consisting of the amino acid sequence of SEQ ID NO: 10; and
vi. a CDR3 consisting of the amino acid sequence of SEQ ID NO: 14;

g) a first ISVD specifically binds to the constant domain of a TCR on a T cell and comprises:
i. a CDR1 consisting of the amino acid sequence of SEQ ID NO: 6;
ii. a CDR2 consisting of the amino acid sequence of SEQ ID NO: 10; and
iii. a CDR3 consisting of the amino acid sequence of SEQ ID NO: 14; and

 a second ISVD specifically binds to GPC3 and comprises:
iv. a CDR1 consisting of the amino acid sequence of SEQ ID NO: 8;
v. a CDR2 consisting of the amino acid sequence of SEQ ID NO: 12; and
vi. a CDR3 consisting of the amino acid sequence of SEQ ID NO: 16; or

h) a first ISVD specifically binds to GPC3 and comprises:
i. a CDR1 consisting of the amino acid sequence of SEQ ID NO: 8;
ii. a CDR2 consisting of the amino acid sequence of SEQ ID NO: 12; and
iii. a CDR3 consisting of the amino acid sequence of SEQ ID NO: 16; and

 a second ISVD specifically binds to the constant domain of a TCR on a T cell and comprises:
iv. a CDR1 consisting of the amino acid sequence of SEQ ID NO: 6;
v. a CDR2 consisting of the amino acid sequence of SEQ ID NO: 10; and
vi. a CDR3 consisting of the amino acid sequence of SEQ ID NO: 14

wherein the order of the ISVDs indicates their relative position to each other considered from the N-terminus to the C-terminus of said polypeptide.